| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
318.56(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.14 - $13.81 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300 |
30,300 |
| Total Buy Value |
$0 |
$0 |
$863 |
$132,633 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
0 |
0 |
0 |
155,302 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fusco Joan |
SVP, Operations |
• – – |
2009-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
23,312 |
40,812 |
|
- |
|
| Morges Wayne |
VP, Regulatory Affairs & Qual |
• – – |
2009-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
25,591 |
38,091 |
|
- |
|
| Riddle Valerie D |
VP, Medical Director |
• – – |
2009-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
27,503 |
58,824 |
|
- |
|
| Cook Francesca M |
VP, Policy & Govt. Affairs |
• – – |
2009-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
25,737 |
45,838 |
|
- |
|
| Wright David P |
President and CEOMember of Sec |
• • – |
2008-12-01 |
4 |
B |
$0.95 |
$12,350 |
D/D |
13,000 |
337,315 |
2.81 |
- |
|
| Wright David P |
President and CEOMember of Sec |
• • – |
2008-11-25 |
4 |
B |
$0.98 |
$686 |
D/D |
700 |
324,315 |
2.73 |
- |
|
| Wright David P |
President and CEOMember of Sec |
• • – |
2008-11-21 |
4 |
B |
$0.93 |
$15,345 |
D/D |
16,500 |
323,615 |
2.81 |
- |
|
| Wright David P |
President and CEOMember of Sec |
• • – |
2008-11-20 |
4 |
B |
$0.98 |
$49,000 |
D/D |
50,000 |
307,115 |
2.81 |
- |
|
| Wright David P |
President and CEOMember of Sec |
• • – |
2008-11-19 |
4 |
B |
$0.96 |
$43,488 |
D/D |
45,300 |
257,115 |
2.81 |
- |
|
| Price Kevin |
President-Pharmathene UK, Ltd. |
• – – |
2008-11-19 |
4 |
B |
$0.95 |
$2,375 |
D/D |
2,500 |
2,500 |
2.66 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2008-06-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,122,000 |
|
- |
|
| Wright David P |
President and CEOMember of Sec |
• • – |
2008-05-29 |
4 |
B |
$2.90 |
$7,250 |
D/D |
2,500 |
211,815 |
2.81 |
- |
|
| Wright David P |
President and CEOMember of Sec |
• • – |
2008-05-28 |
4 |
B |
$2.91 |
$21,825 |
D/D |
7,500 |
209,315 |
2.81 |
- |
|
| Fusco Joan |
Sr Vice President, OperationsO |
• – – |
2008-02-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,500 |
|
- |
|
| Morges Wayne |
VP, Regulatory Affairs |
• – – |
2007-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
12,500 |
|
- |
|
| Camut Christopher C |
Chief Financial Officer |
• – – |
2007-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
24,000 |
24,000 |
|
- |
|
| Cook Francesca M |
VP, Policy & Govt Affairs |
• – – |
2007-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
20,101 |
|
- |
|
| Richman Eric I |
Sr. VP, Business Development |
• – – |
2007-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Riddle Valerie D |
VP, Medical Director |
• – – |
2007-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
31,321 |
|
- |
|
| Wright David P |
Chief Executive OfficerMember |
• • – |
2007-08-30 |
4/A |
A |
$0.00 |
$0 |
D/D |
100,000 |
201,815 |
|
- |
|
| Wright David P |
Chief Executive OfficerMember |
• • – |
2007-08-10 |
4/A |
A |
$0.00 |
$0 |
D/D |
1,274 |
101,815 |
|
- |
|
| Wright David P |
Chief Executive OfficerMember |
• • – |
2007-08-10 |
4/A |
A |
$0.00 |
$0 |
D/D |
1,274 |
101,816 |
|
- |
|
| Simon Nicholas J III |
10% Owner |
– – • |
2007-08-07 |
4/A |
B |
$7.70 |
$962,500 |
I/I |
125,000 |
3,489,443 |
1.5 |
- |
|
| Mpm Asset Management Investors 2004 Bviii Llc |
10% Owner |
– – • |
2007-08-07 |
4/A |
B |
$7.70 |
$962,500 |
I/I |
125,000 |
3,489,443 |
1.5 |
- |
|
| Pappajohn John |
Chairman and Secretary |
• • – |
2007-08-07 |
4 |
B |
$7.70 |
$770,000 |
D/D |
100,000 |
1,182,000 |
2.81 |
- |
|
417 Records found
|
|
Page 14 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.22 (3.51%) 
